Company environment · Targeted small molecules · as-filed efficacy
Targeted oncology small-molecule NDA freeze
Initial NDA sequence being locked for FDA CDER submission.
1What does this company do?
Originator oncology sponsor locking an initial NDA submission for a targeted kinase inhibitor.
2Where is the product on its way to patients?
Oral targeted oncology small molecule at initial NDA sequence freeze.
- 1Discovery & Lead Selection
- 2IND-Enabling Nonclinical
- 3Clinical Development (IND / CTA)
- 4Registration & Dossier Review
- The product is here
- 5Approval & Launch Readiness
- 6Commercial Lifecycle & GMP
3What is happening right now?
The eCTD sequence freezes today, and the working Module 2.7.3 draft still carries an earlier investigator outline.
4Tasks
1 task in the 81-task Biopharma Bench V0.2 suite, graded against expert rubric criteria.
Sealed partner records & open showcases
This environment is reconstructed from a confidential drug or device program, so its records, tasks, and rubrics remain sealed.
To inspect complete workspaces, candidate deliverables, trajectories, and rubric criteria end to end, open the two public companion showcases:
Havenor Therapeutics (synthetic sterile-injectables CMC/MSAT) →
Broad Institute (public FDA CDER IND 167326 record) →